Document is current

Article History

Received: 28 December 2020

Accepted: 24 April 2021

First Online: 30 April 2021

Declarations

:

: As noted in the primary reports of the BERSON [CitationRef removed, CitationRef removed] and BANTING [CitationRef removed] studies, all participants gave informed consent to participate, and the study protocols and amendments were approved by the appropriate ethics review boards at each study site.

: Not applicable.

: AJ Lorenzatti was the Principal Investigator in the BERSON trial and reports research support from Amgen, Novo Nordisk and Esperion; a consulting role for Amgen, Kowa, and PTC; and speaking activities with Amgen, Novo Nordisk, Pfizer, and PTC. RS Rosenson reports research support from Amgen, Novartis, NIH, and Regeneron; consulting/advisory roles for Amgen, Amyrt C5, CVS Caremark, The Medicines Company, Novartis, Regeneron, and 89 BioMedicines Company; speaking (non-promotional) roles with Amgen, Kowa, and Regeneron; stock holdings with MediMergent; royalties from Wolters Kluwer (UpToDate); and patents for biocellular inflammatory pathways. ML Monsalvo, JAG López, and H Wang are employees and shareholders of Amgen.